ClinicaliQ Trial Snapshot
- Optical Coherence Tomography And NEphropathy: The OCTANE Study — Recruiting • Cardiology / Cardiovascular • NCT02132741.
- What is being tested: Optical coherence tomography (OCT) imaging to detect structural and functional changes in blood vessels in patients with hypertension and chronic kidney disease, aiming to identify vascular damage that contributes to cardiovascular and cerebrovascular risk.
- Patient eligibility overview: The study focuses on patients with concurrent hypertension and chronic kidney disease, a population at significantly elevated risk of adverse cardiovascular outcomes including heart disease and stroke.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of the eye. It is a…
Eligibility Snapshot
- : * Male or female * Age 18-80 * Body mass index ≤35 * For those with hypertension: BP ≥140/90 or on treatment for hypertension * For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.